89Zr-DFO-CZP

N/A

Report date: 2025/09/24 17:41:58

NME

Base Information

Drug Name89Zr-DFO-CZP

Drug Alias Name89Zr-DFO-Certolizumab pegol89Zr-CimziaZirconium-89 Certolizumab[89Zr]DFO-CZP89Zr-DFO-CZP

ClassificationRadiation-emitting products > Nuclides > Zirconium > 89ZrRadiation-emitting products > Radioactive diagnostic agentRadiation-emitting products > Radionuclide Drug Conjugates

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsArthritis, Rheumatoid

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesUc San Francisco

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesUc San Francisco

Active IndicationsN/A

Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A